Patients with acute myeloid leukemia and an activating mutation in FLT3 respond to a small-molecule FLT3 tyrosine kinase inhibitor, PKC412
Authors
Richard Stone,
Daniel DeAngeloVirginia Klimek,
Ilene Galinsky,
Elihu Estey,
Stephen Nimer,
Wilson Grandin,
David Lebwohl,
Yanfeng Wang,
Pamela Cohen,
Edward Fox,
Donna Neuberg,
Jennifer Clark,
D. Gilliland +12 authors
,
James Griffin Tip Tip